Kenneth Croitoru

Mount Sinai Hospital — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

48h-index9.9kcitations261works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(128), Microscopic Colitis(76), Gut microbiota and health(54), Helicobacter pylori-related gastroenterology studies(25), Eosinophilic Esophagitis(23)

Publications252 total

Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials
Gut·2025· 3 cited
Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study
JEADV Clinical Practice·2025Open Access
IBD Prediction Is Possible, but How Far Are We from Implementing It?
Inflammatory Bowel Diseases·2025· 2 cited
Metabolomics reveal distinct molecular pathways associated with future risk of Crohn’s Disease
Gut Microbes·2025· 3 citedOpen Access
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease
United European Gastroenterology Journal·2025· 2 citedOpen Access
DUOX2-mediated gut barrier dysfunction: a preclinical mechanism in IBD pathogenesis?
Gut·2025· 1 cited
Sa1885: MAGIC IN IMAGINE: NO DIFFERENCES IN SYMPTOMS EXPERIENCED ACROSS UC PHENOTYPES
Gastroenterology·2025
1006: ASSOCIATIONS OF FERMENTABLE FIBER INTAKE WITH CROHN’S DISEASE RISK AND RELATED BIOMARKERS IN FIRST-DEGREE RELATIVES: A GEM PROJECT UPDATE
Gastroenterology·2025
Sa1773: ASSOCIATION OF MICROBIOME WITH RISK OF CROHN’S DISEASE: A STRATIFIED ANALYSIS BASED ON FECAL CALPROTECTIN LEVELS
Gastroenterology·2025
743: ANTI-GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR AUTOANTIBODIES DEFINE A DISTINCT SUB-PHENOTYPE OF CROHN’S DISEASE
Gastroenterology·2025
196: DEFINING THE PRECLINICAL SIGNATURES OF THE MICROBIOME, METABOLOME, PROTEOME, AND ANTI-MICROBIAL ANTIBODY RESPONSES ASSOCIATED WITH FUTURE RISK OF ULCERATIVE COLITIS.
Gastroenterology·2025
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design
˜The œLancet. Gastroenterology & hepatology·2025· 11 citedOpen Access
Reply
Gastroenterology·2025Open Access
Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health
Journal of Crohn s and Colitis·2025· 18 citedOpen Access
Reply
Gastroenterology·2025Open Access
Dietary fibre counters the oncogenic potential of colibactin-producing Escherichia coli in colorectal cancer
Nature Microbiology·2025· 18 cited
Epstein-Barr Virus Exposure Precedes Crohn's Disease Development
Gastroenterology·2025· 13 cited
A148 <i>NOD2</i> LIGAND AND PEPTIDOGLYCAN HYDROLASE GENE ABUNDANCES ARE ALTERED IN PRE-CROHN’S DISEASE
Journal of the Canadian Association of Gastroenterology·2025· 1 citedOpen Access
A73 MICROBIAL CONTRIBUTION TO THE RISK OF FUTURE CROHN’S DISEASE: STRATIFICATION BY SUBCLINICAL INFLAMMATION LEVELS MEASURED BY FECAL CALPROTECTIN
Journal of the Canadian Association of Gastroenterology·2025· 1 citedOpen Access
Symptoms in Persons With Either Active or Inactive Crohn‘s Disease Are Agnostic to Disease Phenotype
Journal of Clinical Gastroenterology·2025
page 1 of 13Next →

Frequent Co-authors

Mark S. Silverberg(20), Williams Turpin(16), Anne M. Griffiths(15), A. Hillary Steinhart(14), Guy Aumais(14), Kevan Jacobson(13), Çharles N. Bernstein(13), David S. Guttman(12), Paul Moayyedi(12), Dan Turner(11), John K. Marshall(11), Alain Bitton(10), Juan A. Raygoza Garay(9), Remo Panaccione(9), Anthony Otley(9), Ernest G. Seidman(9), Maria Cino(9), Colette Deslandres(9), Hien Q. Huynh(9), Osvaldo Espin‐Garcia(8)